Bibliografia

 1. Zhu H, Bi D, Zhang Y, Kong C, Du J, Wu X, Wei Q, Qin H. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. Signal Transduct Target Ther. Jan 17;7(1):11. (2022)

2. American Diabetes, A. 2. Classification and diagnosis of diabetes. Diabetes Care 40, S11–S24 (2017).

3. American Diabetes, A. et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 31(Suppl 1), S61–78 (2008).

4. Rizza, R. A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 59, 2697–2707 (2010).

5. Gannon, M. C., Hoover, H. & Nuttall, F. Q. Further decrease in glycated hemoglobin following ingestion of a LoBAG30 diet for 10 weeks compared to 5 weeks in people with untreated type 2 diabetes. Nutr. Metab. 7, 64 (2010).

6. Nuttall, F. Q., Schweim, K., Hoover, H. & Gannon, M. C. Effect of the LoBAG30 diet on blood glucose control in people with type 2 diabetes. Br. J. Nutr. 99, 511–519 (2008).

7. Dashti, H. M. et al. Beneficial effects of ketogenic diet in obese diabetic subjects. Mol. Cell Biochem. 302, 249–256 (2007).

8. Hussain, T. A. et al. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes. Nutrition 28, 1016 1021 (2012).

9. Rafiullah, M., Musambil, M. & David, S. K. Effect of a very low-carbohydrate ketogenic diet vs recommended diets in patients with type 2 diabetes: a metaanalysis. Nutr. Rev. https://doi. org/10.1093/nutrit/nuab040 (2021)

10. Yuan, X. et al. Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and metaanalysis. Nutr. Diabetes 10, 38–38 (2020).

11. Castaldo, G. et al. Aggressive nutritional strategy in morbid obesity in clinical practice: safety, feasibility, and effects on metabolic and haemodynamic risk factors. Obes. Res. Clin. Pract. 10, 169–177 (2016).

12. Dashti, H. M. et al. Long-term effects of a ketogenic diet in obese patients. Exp. Clin. Cardiol. 9, 200–205 (2004)

13. Choi, Y. J., Jeon, S.-M. & Shin, S. Impact of a ketogenic diet on metabolic parameters in patients with obesity or overweight
and with or without type 2 diabetes: a meta-analysis of randomized controlled trials. Nutrients 12, 2005 (2020)

14. Watanabe, M. et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature. Obes. Rev. 21, e13024 (2020).

15. Paoli, A. et al. Long term successful weight loss with a combination biphasic ketogenic Mediterranean diet and Mediterranean diet maintenance protocol. Nutrients 5, 5205–5217 (2013)

16. Mardinoglu, A. et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab. 27, 559–571 e555 (2018)

17. Gibson, A. A. et al. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes. Rev. 16, 64–76 (2015).

18. Shimazu, T. et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).

19. Mavropoulos, J. C., Yancy, W. S., Hepburn, J. & Westman, E. C. The effects of a low carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr. Metab. 2, 35 (2005).

20. Gower, B. A. et al. Favourable metabolic effects of a eucaloric lowercarbohydrate diet in women with PCOS. Clin. Endocrinol. 79, 550–557 (2013).

21. Paoli, A. et al. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J. Transl. Med. 18, 104 (2020).

22. Burghen, G. A., Givens, J. R. & Kitabchi, A. E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50, 113–116 (1980).

23. Nestler, J. E. et al. Insulin stimulates testo sterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83, 2001–2005 (1998).

24. Rusek, M., Pluta, R., Ulamek-Koziol, M. & Czuczwar, S. J. Ketogenic diet in Alzheimer’s disease. Int. J. Mol. Sci 20, 3892 (2019)

25. Soria Lopez, J. A., Gonzalez, H. M. & Leger, G. C. Alzheimer’s disease. Handb. Clin. Neurol. 167, 231–255 (2019).

26. Macdonald, R., Barnes, K., Hastings, C. & Mortiboys, H. Mitochondrial abnormalities in Parkinson’s disease and Alzheimer’s disease: can mitochondria be targeted therapeutically? Biochem. Soc. Trans. 46, 891–909 (2018).

27. McDonald, T. J. W. & Cervenka, M. C. Ketogenic diets for adult neurological disorders. Neurotherapeutics 15, 1018 1031 (2018).

28. Kashiwaya, Y. et al. D-beta-hydroxy butyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc. Natl Acad. Sci. USA 97, 5440–5444 (2000).

29. Costantini, L. C., Barr, L. J., Vogel, J. L. & Henderson, S. T. Hypometabolism as a therapeutic target in Alzheimer’s disease. BMC Neurosci. 9(Suppl 2), S16 (2008).

30. Johri, A. & Beal, M. F. Mitochondrial dysfunction in neurodegenerative diseases. J. Pharm. Exp. Ther. 342, 619 630 (2012).

31. Pinto, A. et al. Anti-oxidant and anti inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer’s disease. Antioxidants 7, 63 (2018).

32. Holmes, C. Review: systemic inflammation and Alzheimer’s disease. Neuropa thol. Appl. Neurobiol. 39, 51–68 (2013).

33. Joniec-Maciejak, I. et al. Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson’s disease. Pharm. Rep. 70, 988–992 (2018).

34. Yang, X. & Cheng, B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J. Mol. Neurosci. 42, 145–153 (2010)

35. Singh, A. & Trevick, S. The epidemiology of global epilepsy. Neurol. Clin. 34, 837 847 (2016).

36. Thurman, D. J. et al. The primary prevention of epilepsy: a report of the Prevention Task Force of the International League Against Epilepsy. Epilepsia 59, 905–914 (2018).

37. Martin, K., Jackson, C. F., Levy, R. G. & Cooper, P. N. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst. Rev. 2, CD001903 (2016).

38. Ulamek-Koziol, M., Czuczwar, S. J., Januszewski, S. & Pluta, R. Ketogenic diet and epilepsy. Nutrients 11, 2510 (2019).

39. Pehrson, A. L. & Sanchez, C. Altered gamma-aminobutyric acid neuro transmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des. Devel Ther. 9, 603–624 (2015).

40. Nagpal, R. et al. Modified Mediterranean ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine 47, 529–542 (2019).

41. Bandelow, B. & Michaelis, S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin. Neurosci. 17, 327–335 (2015).

42. Forte, N. et al. 2-Deoxy-d-glucose enhances tonic inhibition through the neurosteroid-mediated activation of extrasynaptic GABA receptors. Epilepsia 57, 1987–2000 (2016).

43. Ereci?ska, M., Nelson, D., Daikhin, Y. & Yudkoff, M. Regulation of GABA level in rat brain synaptosomes: fluxes through
enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies. J. Neurochem. 67, 2325–2334 (1996)

44. Weber, D. D. et al. Ketogenic diet in the treatment of cancer—where do we stand? Mol. Metab. 33, 102–121 (2020)

45. Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016). 236. Seyfried, T. N. et al. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br. J. Cancer 89, 1375–1382 (2003)

46. Hao, G. W. et al. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac. J. Cancer Prev. 16, 2061–2068 (2015).

47. Shang, S. et al. The Beta-Hydroxybutyrate Suppresses the Migration of Glioma Cells by Inhibition of NLRP3 Inflammasome. Cell Mol. Neurobiol. 38, 1479–1489 (2018).

48. Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698–705 (2016). 259.

49. Bedi, K. C. Jr. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133, 706–716 (2016).

50. Horton, J. L. et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight 4, e124079 (2019).

51. Nielsen, R. et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation 139, 2129 2141 (2019).

52. Kong, C. et al. Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome. Signal Transduct. Target. Ther. 6, 154 (2021)

53. Chimienti, G. et al. The ketogenic diet reduces the harmful effects of stress on gut mitochondrial biogenesis in a rat model of irritable bowel syndrome. Int. J. Mol. Sci 22, 3498 (2021)

54. Schiavo, L., Pilone, V., Rossetti, G., Barbarisi, A., Cesaretti, M., & Iannelli, A. A 4-Week Preoperative Ketogenic Micronutrient Enriched Diet Is Effective in Reducing Body Weight, Left Hepatic Lobe Volume, and Micronutrient Deficiencies in Patients Undergoing Bariatric Surgery: a Prospective Pilot Study. Obesity surgery, 28(8), 2215–2224 (2018)

55. Pilone, V., Tramontano, S., Renzulli, M., Romano, M., Cobellis, L., Berselli, T., & Schiavo, L. Metabolic effects, safety, and acceptability of very low-calorie ketogenic dietetic scheme on candidates for bariatric surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 14(7), 1013–1019 (2018)

56. Schiavo, L., De Stefano, G., Persico, F., Gargiulo, S., Di Spirito, F., Griguolo, G., Petrucciani, N., Fontas, E., Iannelli, A., & Pilone, V. A Randomized, Controlled Trial Comparing the Impact of a Low-Calorie Ketogenic vs a Standard Low-Calorie Diet on Fat-Free Mass in Patients Receiving an Elipse™ Intragastric Balloon Treatment. Obesity surgery, 31(4), 1514–1523 (2021)

57. Schiavo, L., Pierro, R., Asteria, C., Calabrese, P., Di Biasio, A., Coluzzi, I., Severino, L., Giovanelli, A., Pilone, V., & Silecchia, G. Low-Calorie Ketogenic Diet with Continuous Positive Airway Pressure to Alleviate Severe Obstructive Sleep Apnea Syndrome in Patients with Obesity Scheduled for Bariatric/ Metabolic Surgery: a Pilot, Prospective, Randomized Multicenter Comparative Study. Obesity surgery, 32(3), 634–642 (2022)

58. Albanese, A., Prevedello, L., Markovich, M., Busetto, L., Vettor, R., & Foletto, M. Pre operative Very Low Calorie Ketogenic Diet (VLCKD) vs. Very Low Calorie Diet (VLCD): Surgical Impact. Obesity surgery, 29(1), 292–296 (2019)

59. Migrain remans second amog the world’s causes of disability, and first among young womem : findigs from GBD 2019 T:J: steiner et al. : J Headache pain 2020; 21 (1):37

60. Razeghi Jahromi S, Ghorbani Z, Martelletti P, et.Al; Association of diet and headache. J Headache Pain 2019; 20 (1):106

61. Linee guida per diagnosi e terapia delle cefalee primaria 2011. Società Italiana per lo Studio della Cefalee

62. Winesett SP, Bessone SK, Kossoff EH. The ketogenic diet in pharmacoresistant childhood epilepsy. Expert Rev Neueother 2015; 15(6):621-628

63. Paoli A, Rubini A, Volek JS, et al. Beyond wheight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J ClinNutr 2013;67(8):789-796.

64. Barbanti P, Fofi L, Aurilia C, et al. Ketogenic diet in migraine: rationale, findings and prospectives. Neurol Sci 2017; (Suppl1): 11-115